Key Points
- Matrix Capital Management sold 7,500,000 shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on Dec. 15 at an average price of $1.33 for about $9.98 million, cutting its holdings by 53.73% to 6,459,973 shares.
- ZNTL shares trade around $1.40 (1‑year range $1.01–$3.33) with a market capitalization near $101.15 million and a negative P/E, reflecting its position as a small‑cap clinical‑stage biotech.
- The company beat the most recent quarterly EPS estimate (‑$0.37 vs. consensus ‑$0.49), but analysts still project a full‑year EPS of about ‑2.42; consensus analyst coverage is a Hold with an average target of $4.53 and mixed ratings.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the sale, the insider directly owned 6,459,973 shares of the company's stock, valued at approximately $8,591,764.09. This trade represents a 53.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Zentalis Pharmaceuticals Price Performance
Shares of NASDAQ:ZNTL opened at $1.40 on Tuesday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $3.33. The stock has a market capitalization of $101.15 million, a price-to-earnings ratio of -0.68 and a beta of 1.75. The company's 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.47.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.12. As a group, analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
Several large investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company's stock worth $48,000 after purchasing an additional 8,236 shares during the last quarter. State of Wyoming raised its position in Zentalis Pharmaceuticals by 30.1% during the 1st quarter. State of Wyoming now owns 45,176 shares of the company's stock worth $72,000 after purchasing an additional 10,460 shares during the last quarter. American Century Companies Inc. raised its position in Zentalis Pharmaceuticals by 46.2% during the 1st quarter. American Century Companies Inc. now owns 46,900 shares of the company's stock worth $75,000 after purchasing an additional 14,816 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Zentalis Pharmaceuticals by 4.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,236 shares of the company's stock worth $574,000 after buying an additional 16,197 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company's stock valued at $4,386,000 after buying an additional 19,768 shares during the last quarter.
Analyst Ratings Changes
Several research analysts have commented on ZNTL shares. Leerink Partners reissued a "market perform" rating and set a $2.00 target price on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, November 16th. Morgan Stanley decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of "Hold" and an average target price of $4.53.
Check Out Our Latest Report on Zentalis Pharmaceuticals
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
